Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.895 USD | -0.56% | +1.64% | -31.15% |
Mar. 26 | Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 19 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 792.9 | 29.19 | 4.323 | 3.018 | 6.528 | - | - |
Enterprise Value (EV) 1 | 792.9 | 29.19 | 4.323 | 3.018 | 6.528 | 6.528 | 6.528 |
P/E ratio | -3.58 x | -0.45 x | -0.16 x | -0.16 x | -0.43 x | -0.88 x | -1.18 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 1.31 x | 1.31 x |
EV / Revenue | - | - | - | - | - | 1.31 x | 1.31 x |
EV / EBITDA | - | - | - | -0.2 x | -0.48 x | -1.09 x | -0.69 x |
EV / FCF | - | - | - | - | -0.58 x | -2.11 x | -0.8 x |
FCF Yield | - | - | - | - | -172% | -47.5% | -126% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 3,722 | 628 | 2,078 | 2,321 | 7,294 | - | - |
Reference price 2 | 213.0 | 46.50 | 2.080 | 1.300 | 0.8950 | 0.8950 | 0.8950 |
Announcement Date | 4/1/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 5 | 5 |
EBITDA 1 | - | - | - | -14.77 | -13.7 | -6 | -9.4 |
EBIT 1 | - | -25.94 | -19.96 | -16.45 | -16.29 | -16.34 | -18.72 |
Operating Margin | - | - | - | - | - | -326.74% | -374.3% |
Earnings before Tax (EBT) 1 | - | -56.43 | - | -17.26 | -17.98 | -13.81 | -16.72 |
Net income 1 | -6.865 | -48.98 | -18.47 | -17.46 | -17.98 | -13.81 | -16.72 |
Net margin | - | - | - | - | - | -276.11% | -334.45% |
EPS 2 | -59.50 | -103.5 | -13.00 | -8.090 | -2.080 | -1.020 | -0.7600 |
Free Cash Flow 1 | - | - | - | - | -11.2 | -3.1 | -8.2 |
FCF margin | - | - | - | - | - | -62% | -164% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/1/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT | -3.517 | -12.3 | -4.796 | -4.707 | -5.657 | -4.802 | - | -5.668 | -3.448 | -2.384 | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -2.712 | -49.56 | -4.524 | -2.872 | -2.479 | - | - | - | - | -3.414 | - | - | - | - | - |
Net income | -2.712 | -42.11 | -4.524 | -2.872 | -2.603 | - | -4.678 | - | - | -3.436 | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -6.000 | -86.50 | -5.500 | -2.730 | -1.460 | - | -2.310 | - | -1.300 | -1.470 | -0.6100 | -0.5500 | -0.5200 | -0.4000 | -0.4000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/31/22 | 5/13/22 | 8/12/22 | 11/14/22 | 3/31/23 | 5/15/23 | 8/11/23 | 11/13/23 | 3/26/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | - | -11.2 | -3.1 | -8.2 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | 0.3 | 0.4 |
Capex / Sales | - | - | - | - | - | 6% | 8% |
Announcement Date | 4/1/21 | 3/31/22 | 3/31/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.15% | 6.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENVB Stock
- Financials Enveric Biosciences, Inc.